scholarly journals Yttrium-90 Radioembolization of Metastatic Adrenocortical Carcinoma to the Liver following Systemic Chemotherapy and Surgical Resection of the Primary Lesion

2020 ◽  
Vol 13 (1) ◽  
pp. 158-163
Author(s):  
Nicholas Pigg ◽  
Daniel Aboubechara ◽  
Roberto Fourzali ◽  
Brian Baigorri
Keyword(s):  
Case Report ◽  
Metastatic Disease ◽  
Adrenocortical Carcinoma ◽  
Liver Tumors ◽  
Primary Liver Tumors ◽  
Off Label ◽  
Metastatic Lesions ◽  
Potential Efficacy ◽  
The Right ◽  
Yttrium 90

Use of yttrium-90 (Y-90) is used for primary liver tumors and a handful of liver metastatic lesions. Y-90 treatment for metastatic adrenocortical carcinoma (ACC) to the liver is currently off-label, with one previously documented case report. In this case report, we present a 52-year-old woman with ACC and extensive liver metastatic disease. After failed chemotherapy, multidisciplinary discussion suggested potential Y-90 treatment for palliative purposes. After undergoing Y-90 treatment separately to the right and then the left hepatic lobes, subsequent patient visits demonstrated significantly improved clinical function as well as complete radiographic resolution of liver metastatic disease mainly from ACC. This case report demonstrates the potential efficacy of Y-90 for off-label uses in liver metastatic disease. This case and similar cases may open the door to a wide variety of potential indications for Y-90 treatment.

Tumor growth rate in metastatic adrenocortical carcinoma using two-dimensional computer tomography scan.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e16125-e16125
Author(s):  
Sarah N. Fuller ◽  
Ahmad Shafiei ◽  
Maran Ilanchezhian ◽  
Mohammadhadi Bagheri ◽  
Jaydira Del Rivero
Keyword(s):  
Growth Rate ◽  
Lymph Node ◽  
Metastatic Disease ◽  
Computer Tomography ◽  
Adrenocortical Carcinoma ◽  
Liver Lesions ◽  
Two Dimensional ◽  
Lung Lesions ◽  
Metastatic Lesions ◽  
Computer Tomography Scan

e16125 Background: Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of 1.5–2 per million people per year. It has a poor prognosis with an overall 5-year mortality of 75-80%. The treatment of choice for a localized primary or recurrent tumor is radical surgical resection. However, patients with recurrent or metastatic disease are infrequently cured by surgery alone and chemotherapy has limited benefits. Little is known about the growth rate of metastatic lesions or how disease burden varies among patients, which poses a considerable obstacle in patient care as 17–53% of patients present with distant metastases at the time of diagnosis. Most ACC metastases are found in the liver, lung, bone, and retroperitoneum. Methods: This study retrospectively analyzed the growth rate of metastatic ACC lesions in the lung, liver, lymph nodes, and adrenal bed using serial two-dimensional segmentation of computer tomography images from 10 patients seen at the National Institutes of Health. All patients were females (mean age of 61 years; range, 49–70 years) who had an ACC diagnosis for a mean of 7 years (range, 3–14 years). Only lesions that exhibited FGD-PET avidity were included with up to five lesions per organ recorded. Results: Of the 10 patients, 7 showed metastatic disease at primary diagnosis, although all patients developed recurrent and/or distant metastatic lesions throughout the course of their disease (3 patients had lung lesions, 6 had liver lesions, 8 had adrenal bed recurrence, and 5 had lymph node involvement). Compared over a 6-month period without treatment alteration (change in chemotherapy, surgical intervention, or ablation) lung lesions increased by 11.6%, liver lesions decreased by 17.9%, retroperitoneal lesions increased by 69.25%, and lymph node lesions increased by 9.2%. Conclusions: Treatment of metastatic lesions, particularly in the liver, can increase long-term survival. Understanding growth rates of metastatic tumors may lead to improved treatment of patients with ACC.

Metastases resection in colorectal cancer patients with mutation in oncogene BRAF or tumors located on the right side: Experience at the HGUGM.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 4041-4041
Author(s):  
Laura Ortega ◽  
Marianela Bringas Beranek ◽  
Natalia Gutiérrez Alonso ◽  
Javier Soto Alsar ◽  
Manuel Alva Bianchi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Overall Survival ◽  
Metastatic Disease ◽  
Positive Impact ◽  
Wild Type ◽  
Primary Tumors ◽  
Metastatic Lesions ◽  
Common Location ◽  
The Right ◽  
The Impact

4041 Background: Approximately 25% of patients with colorectal cancer (CRC) debut with metastatic disease. In addition, 25-35% of patients with localized disease at diagnosis develop metastatic lesions during the evolution of their disease. Consequently, approximately 50-60% of patients with CRC will present metastatic lesions at some point in their lives. Metastasis resection has improved the prognosis of these patients, achieving overall survival (OS) that exceed 40 months. However, there are doubts about the benefit of this approach in patients with mutations in oncogene BRAF or tumors located on the right-side, due their poor prognosis. The aim of the study is to analyze the impact of metastases resection on OS of these populations. Methods: We conducted a retrospective analysis of patients with mCRC attended in the Medical Oncology Department of the Hospital General Universitario Gregorio Marañón (Spain) between January 2010 and 2018. Results: 487 patients were identified and included in the analysis. Median age was 71 years (62-81). Most patients were males (62.4%). 55.2% had metastatic lesions at diagnosis. Most patients had ECOG 0-1 at diagnosis of metastatic disease (91.0%). 8.9% of patients had BRAF mutations (n = 21) and 31.8% of patients had primary tumors located on the right-side (n = 152). 474 patients received first-line chemotherapy (97.3%). OS of the entire cohort was 29.67 months; 30.69 months in BRAF mutated patients vs 35.89 in wild-type patients (p = 0.161); 25.29 months in right-side tumors vs 31.02 in left-side tumors (p = 0.044). 306 patients (62.8%) underwent metastases resection. Most common location was liver (51.4%). 147 patients (30.2%) underwent a second metastases resection. Mean number of metastases surgeries was 1.35 (+/-1.40). OS since metastases resection was 24.83 months in BRAF mutated patients vs 41.55 months in wild-type patients (p = 0.020). According to location, it was 35.49 months in right-side tumors vs 43.78 months in left-side tumors (p = 0.106). In BRAF mutated patients, OS was 38.19 months in patients underwent metastases resection vs 18.52 months in non-surgical patients (p = 0.043); 41.51 months vs 16.18 months respectively in patients with tumors located on the right-side (p < 0.001). Conclusions: Metastases resection has a positive impact on overall survival of patients with mutations in oncogene BRAF or right-side tumors, even though their prognosis is still poor compared to patients without these alterations.

Recognizing and Managing Adverse Events in Y-90 Radioembolization

2021 ◽  
Vol 38 (04) ◽  
pp. 453-459
Author(s):  
Grace L. Laidlaw ◽  
Guy E. Johnson
Keyword(s):  
Adverse Events ◽  
Patient Care ◽  
Liver Tumors ◽  
Hepatic Metastases ◽  
Systemic Effects ◽  
Primary Liver Tumors ◽  
Transarterial Radioembolization ◽  
Prevention And Treatment ◽  
Yttrium 90

AbstractTransarterial radioembolization using yttrium-90 (Y-90) microspheres is an important therapy in the management of unresectable primary liver tumors or hepatic metastases. While radioembolization is generally well-tolerated, it is not free from adverse events, and familiarity with the prevention and treatment of radioembolization-specific complications is an important component of patient care. This article aims to review radioembolization-specific toxicities stratified by hepatic, extrahepatic, and systemic effects, with a focus on preventing and mitigating radioembolization-induced morbidity.

Treatment of Primary Liver Tumors with Yttrium-90 Microspheres (TheraSphere®) in High Risk Patients: Analysis of Survival and Toxicities

2009 ◽  
Vol 8 (1) ◽  
pp. 71-77 ◽  
Author(s):  
Kelli A. Reardon ◽  
Alyson F. McIntosh ◽  
A. Tanner Shilling ◽  
Klaus D. Hagspiel ◽  
Abdullah Al-Osaimi ◽  
...  
Keyword(s):  
High Risk ◽  
Liver Tumors ◽  
Primary Liver Tumors ◽  
High Risk Patients ◽  
Risk Patients ◽  
Yttrium 90

Malignant Rhabdoid Tumor Mimicking Hepatoblastoma: A Case Report and Literature Review

2007 ◽  
Vol 10 (5) ◽  
pp. 409-415 ◽  
Author(s):  
Lars M. Wagner ◽  
Jennifer K. Garrett ◽  
Edgar T. Ballard ◽  
D. Ashley Hill ◽  
Arie Perry ◽  
...  
Keyword(s):  
Case Report ◽  
Liver Tumors ◽  
Correct Diagnosis ◽  
Rhabdoid Tumor ◽  
Molecular Techniques ◽  
Malignant Rhabdoid Tumor ◽  
Primary Liver Tumors ◽  
Diagnostic Confusion ◽  
Rhabdoid Tumors ◽  
Tumor Types

Hepatoblastoma accounts for the vast majority of malignant primary liver tumors in infancy. In contrast, rhabdoid tumors arising in the liver are extremely rare, but they can share clinical and histologic features with hepatoblastoma and can create diagnostic confusion, especially when one is dealing with small biopsies. In this case report we demonstrate that immunohistochemical and molecular techniques can identify the characteristic loss of INI1 and facilitate making the correct diagnosis of primary hepatic malignant rhabdoid tumor. Important similarities and differences between hepatoblastoma and rhabdoid tumors are reviewed, and suggestions are offered to help distinguish these 2 tumor types.

scholarly journals Labeling of Hinokitiol with 90Y for Potential Radionuclide Therapy of Hepatocellular Carcinoma

Processes ◽  
2021 ◽  
Vol 9 (6) ◽  
pp. 940
Author(s):  
Christelle Bouvry ◽  
Valérie Ardisson ◽  
Nicolas Noiret ◽  
Etienne Garin ◽  
Nicolas Lepareur
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radionuclide Therapy ◽  
Liver Tumors ◽  
Potential Treatment ◽  
Primary Liver Tumors ◽  
Transarterial Radioembolization ◽  
The World ◽  
Yttrium 90

Hepatocellular carcinoma (HCC), the most common form of primary liver tumors, is the fifth cancer in the world in terms of incidence, and third in terms of mortality. Despite significant advances in the treatment of HCC, its prognosis remains bleak. Transarterial radioembolization with radiolabeled microspheres and Lipiodol has demonstrated significant effectiveness. Here we present a new, simple radiolabeling of Lipiodol with Yttrium-90, for the potential treatment of HCC.

scholarly journals Metastatic disease of melanoma malignum choroid

2020 ◽  
Vol 25 (79) ◽  
pp. 55-63
Author(s):  
Snežana Knežević ◽  
Biljana Srećković ◽  
Jelena Vulović
Keyword(s):  
Case Report ◽  
Metastatic Disease ◽  
Skin Color ◽  
Choroidal Melanoma ◽  
Genetic Mutation ◽  
Medical Documentation ◽  
Primary Malignancy ◽  
Long Time ◽  
Melanoma Malignum ◽  
The Right

Introduction. Choroidal melanoma is a rare form of cancer, with a total of 3-5% of the patients suffering from this type of disease. People who are more likely to suffer from the disease are of the white race, bright skin color and iris, as well as those with a genetic mutation BAP 1 and GNAQ. Studies indicate the micro-metastatic disease before the primary process is diagnosed. There is no effective therapy to prevent the development of metastases. In 90% of cases the metastases are in the liver. Metastases can occur any time after the diagnosis of melanoma, even after 40 years. The prognosis of metastatic disease is bad, the median of survival per year is 4 to 15 months. Case report. The patient had enucleation of the eye, when he was primarily treated for malignant melanoma of choroid in 2007. He also appeared regularly for checkups. Felt healthy. 9 years later, dizziness and instability occurred. After a seizure, on July 2016, echotomography and computed tomography diagnosed liver, brain metastases as well as changes in the right lung. Radio-oncology treatment deposits in the brain done with Gama knife, as well as systemic hemotherapy with Dacarbazine. Changes in the lung treated as a secondary deposit. Despite oncology and palliative treatment, the patient passed away 6 months after the diagnosis of the metastatic disease. Conclusion. It is important to point out the importance of early and accurate diagnosis and early treatment of malignant diseases. During the period of monitoring the patient, rare localizations of the metastases must be considered, as well as the possibility of their occurrence long time after the discovery of the primary malignancy. For this case report, the data obtained from extensive medical documentation was used, as well as several years of monitoring patients in Primary care.

Adrenocortical carcinoma with extension into the right atrium: a case report

2014 ◽  
Vol 24 (2) ◽  
pp. 453-456 ◽  
Author(s):  
Elham Farahani ◽  
Fariba Bayat ◽  
Behrang Kazemi-Nejad
Keyword(s):  
Case Report ◽  
Adrenocortical Carcinoma ◽  
Right Atrium ◽  
The Right

scholarly journals A rare case of adult hepatoblastoma mimicking hepatocellular carcinoma- case report and review of literature

2017 ◽  
Vol 4 (4) ◽  
pp. 1478
Author(s):  
Digvijoy Sharma ◽  
Nagari Bheerappa ◽  
Venu Madhav Thumma ◽  
Suryaramchandra Varma ◽  
Kunduru Navakishore ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Tumors ◽  
Primary Tumour ◽  
Primary Liver Tumors ◽  
Adult Age ◽  
Right Lobe ◽  
Triphasic Ct ◽  
Malignant Liver ◽  
The Right ◽  
Operative Recovery

Hepatoblastoma (HB) is a rare malignant primary tumour of the liver and occurs mostly in the pediatric group within the first 3 years of life. It is extremely unusual to find hepatoblastoma in adults and is a very rare cause of primary malignant liver tumour in adults and due to this patient may be diagnosed at late stages of the disease at leading to poor prognosis in this group. Reported here a case of a 20-year-old boy with a large liver mass with abdominal pain. Triphasic CT revealed the presence of a large heterogenous tumor in the right lobe of liver suggestive of hepatocellular carcinoma. Patient underwent a right hepatectomy. Final histopathology was reported as Epithelial type hepatoblastoma. The patient had an uneventful post-operative recovery. We present this case for its rarity and ability to masquerade other primary liver tumors in the adult age as seen in our patient.

Sign in / Sign up

Export Citation Format

Share Document